Skip to main content

NF2 Gene Mutation clinical trials at UCSF
1 in progress, 1 open to new patients

  • Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas

    open to eligible people ages 18 years and up

    This phase II trial studies how well vismodegib and focal adhesion kinase (FAK) inhibitor GSK2256098 work in treating patients with meningioma that is growing, spreading, or getting worse. Vismodegib and FAK inhibitor GSK2256098 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

    Fresno, California and other locations